glow
updated
GLOW usually refers to GHK-Cu, BPC-157, and a TB-500-labeled ingredient. In one component trial, the immediate-treatment plantar subgroup using topical Iamin 2% Gel had greater diabetic-ulcer closure than vehicle; delayed-treatment arms did not outperform vehicle. BPC-157 and thymosin research adds separate preclinical rationale, but no controlled study has tested an identified three-ingredient GLOW formula for skin, hair, or healing.
GHK-Cu + BPC-157 + TB-labeled ingredient
- GHK-Cu + BPC-157 + TB-labeled ingredient
- The recipe and TB identity require confirmation
Does GLOW name one fixed formula?
Products sold as GLOW vary in ingredient amounts, molecular forms, and formulation. The TB ingredient needs particular attention because thymosin beta-4 and its fragments are different substances.
FDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports and marketed combination products. A product being sold or discussed in an advisory meeting does not establish a demonstrated benefit, a safe formulation or FDA approval.
Read the original sourceThree-ingredient GLOW blend evidence
PubMed records
PubMed records for GLOW and its three named ingredients.
The cited PubMed records include studies of individual ingredients and marketing formulas, but no controlled human trial of an identified three-ingredient GLOW formula.
- Ingredient studies and marketing formulas do not establish outcomes for the three-ingredient GLOW blend.
Has this exact combination been tested?
The cited PubMed records include no controlled human trial of an identified three-ingredient GLOW formula. Studies of individual ingredients and marketing formulas do not test the three-ingredient blend.
Three-ingredient GLOW blend evidence
PubMed records
PubMed records for GLOW and its three named ingredients.
The cited PubMed records include studies of individual ingredients and marketing formulas, but no controlled human trial of an identified three-ingredient GLOW formula.
- Ingredient studies and marketing formulas do not establish outcomes for the three-ingredient GLOW blend.
What does component research show for skin, hair, or healing?
In a randomized 181-person diabetic-ulcer trial, the immediate-treatment plantar subgroup using topical Iamin 2% Gel had 98.5% median closure versus 60.8% with vehicle under standardized care. Delayed-treatment arms did not outperform vehicle. BPC-157 and full-length thymosin beta-4 studies add separate preclinical repair and hair-growth findings; they do not establish the TB-500-labeled ingredient. No controlled study has measured skin, hair, or healing outcomes for an identified GLOW blend.
The positive GHK-Cu result came from 28 immediate-treatment plantar-ulcer participants using a defined topical gel after debridement, with pressure-relieving footwear and diabetes-care education. It does not establish the effect of an injectable GLOW vial.
GHK-Cu diabetic-ulcer RCT · 181 participants
Multicenter randomized evaluator-blinded placebo-controlled trial
Mulder GD et al. Wound Repair and Regeneration. 1994;2(4):259-269. doi:10.1046/j.1524-475X.1994.20406.x. PMID: 17147644.
In the immediate-treatment plantar subgroup, Iamin 2% Gel increased median closure to 98.5% versus 60.8% with vehicle and produced a threefold faster closure rate. Delayed-treatment arms did not significantly outperform vehicle.
- Participants / model
- 181 people with diabetes and lower-extremity ulcers; the headline plantar comparison included 28 immediate Iamin 2% Gel participants and 32 immediate vehicle participants
- Treatment
- Once-daily topical Iamin 2% Gel or vehicle immediately after debridement, plus standardized wound care; separate arms began Iamin 2% or 4% Gel after four weeks of vehicle
- Follow-up
- Up to 8 weeks of immediate treatment followed by 6 weeks of observation; delayed arms began active treatment after 4 weeks of vehicle
- Study design
- Multicenter randomized evaluator-blinded placebo-controlled trial
The positive finding came from the immediate-treatment plantar subgroup. This is component evidence for a defined topical GHK-Cu gel, not a trial of GLOW or an injected blend.
Read the original sourceFDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports and marketed combination products. A product being sold or discussed in an advisory meeting does not establish a demonstrated benefit, a safe formulation or FDA approval.
Read the original sourceThymosin beta-4 hair studies · mice and rats
Animal studies
Philp D et al. FASEB Journal. 2004;18(2):385-387. doi:10.1096/fj.03-0244fje. PMID: 14657002.
Full-length thymosin beta-4 promoted hair growth and follicle-cell migration in mouse and rat models.
- Participants / model
- Mouse and rat hair-growth models
- Treatment
- Full-length thymosin beta-4
- Study design
- Animal studies
This is preclinical component evidence for full-length thymosin beta-4, not evidence for a TB-500-labeled ingredient or a GLOW blend.
Read the original sourceThree-ingredient GLOW blend evidence
PubMed records
PubMed records for GLOW and its three named ingredients.
The cited PubMed records include studies of individual ingredients and marketing formulas, but no controlled human trial of an identified three-ingredient GLOW formula.
- Ingredient studies and marketing formulas do not establish outcomes for the three-ingredient GLOW blend.
Is it better than GHK-Cu alone?
A direct comparison is needed to answer that. Neither a higher total peptide weight nor the addition of two proposed repair pathways shows that GLOW performs better.
Does the ingredient with the most milligrams do most of the work?
Mass is not a measure of biological potency or contribution to an outcome. No blend comparison tested whether GHK-Cu accounts for most of the effect.
Three-ingredient GLOW blend evidence
PubMed records
PubMed records for GLOW and its three named ingredients.
The cited PubMed records include studies of individual ingredients and marketing formulas, but no controlled human trial of an identified three-ingredient GLOW formula.
- Ingredient studies and marketing formulas do not establish outcomes for the three-ingredient GLOW blend.
What risks does a three-ingredient vial add?
Side-effect rates for the finished mixture are unknown. FDA identifies safety-data and impurity concerns for BPC-157 and injectable GHK-Cu. Combining ingredients also leaves unanswered questions about their finished formulation and repeated exposure.
FDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA describes limited human safety information for BPC-157 and concerns about impurities, product characterization and immune reactions. For injectable GHK-Cu, it identifies limited human safety data and possible aggregation or peptide impurities.
Read the original sourceWhat is the difference between GLOW and KLOW?
KLOW adds KPV to the usual three-ingredient GLOW grouping. That is an ingredient difference, not evidence that KLOW provides additional gut benefits or that GLOW is a proven aesthetic treatment.
FDA · KPV evidence review
Regulatory safety assessment
FDA · KPV evidence review
The review describes KPV combination marketing and the lack of an adequate human efficacy and safety basis. Proposed gut or tissue-repair uses are not established clinical outcomes for a KPV-containing blend.
Read the original sourceThree-ingredient GLOW blend evidence
PubMed records
PubMed records for GLOW and its three named ingredients.
The cited PubMed records include studies of individual ingredients and marketing formulas, but no controlled human trial of an identified three-ingredient GLOW formula.
- Ingredient studies and marketing formulas do not establish outcomes for the three-ingredient GLOW blend.
What has to match for a study to apply to a GLOW vial?
The study and product must match on every active ingredient, its identity and amount, the formulation and the route. A component paper, a supplier certificate or a clinic testimonial does not establish the outcome of that finished mixture.
FDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports and marketed combination products. A product being sold or discussed in an advisory meeting does not establish a demonstrated benefit, a safe formulation or FDA approval.
Read the original sourceThree-ingredient GLOW blend evidence
PubMed records
PubMed records for GLOW and its three named ingredients.
The cited PubMed records include studies of individual ingredients and marketing formulas, but no controlled human trial of an identified three-ingredient GLOW formula.
- Ingredient studies and marketing formulas do not establish outcomes for the three-ingredient GLOW blend.
Studies and sources
GHK-Cu diabetic-ulcer RCT · 181 participants
Multicenter randomized evaluator-blinded placebo-controlled trial
Mulder GD et al. Wound Repair and Regeneration. 1994;2(4):259-269. doi:10.1046/j.1524-475X.1994.20406.x. PMID: 17147644.
In the immediate-treatment plantar subgroup, Iamin 2% Gel increased median closure to 98.5% versus 60.8% with vehicle and produced a threefold faster closure rate. Delayed-treatment arms did not significantly outperform vehicle.
- Participants / model
- 181 people with diabetes and lower-extremity ulcers; the headline plantar comparison included 28 immediate Iamin 2% Gel participants and 32 immediate vehicle participants
- Treatment
- Once-daily topical Iamin 2% Gel or vehicle immediately after debridement, plus standardized wound care; separate arms began Iamin 2% or 4% Gel after four weeks of vehicle
- Follow-up
- Up to 8 weeks of immediate treatment followed by 6 weeks of observation; delayed arms began active treatment after 4 weeks of vehicle
- Study design
- Multicenter randomized evaluator-blinded placebo-controlled trial
The positive finding came from the immediate-treatment plantar subgroup. This is component evidence for a defined topical GHK-Cu gel, not a trial of GLOW or an injected blend.
Read the original sourceFDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports and marketed combination products. A product being sold or discussed in an advisory meeting does not establish a demonstrated benefit, a safe formulation or FDA approval.
Read the original sourceThymosin beta-4 hair studies · mice and rats
Animal studies
Philp D et al. FASEB Journal. 2004;18(2):385-387. doi:10.1096/fj.03-0244fje. PMID: 14657002.
Full-length thymosin beta-4 promoted hair growth and follicle-cell migration in mouse and rat models.
- Participants / model
- Mouse and rat hair-growth models
- Treatment
- Full-length thymosin beta-4
- Study design
- Animal studies
This is preclinical component evidence for full-length thymosin beta-4, not evidence for a TB-500-labeled ingredient or a GLOW blend.
Read the original sourceFDA · KPV evidence review
Regulatory safety assessment
FDA · KPV evidence review
The review describes KPV combination marketing and the lack of an adequate human efficacy and safety basis. Proposed gut or tissue-repair uses are not established clinical outcomes for a KPV-containing blend.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA describes limited human safety information for BPC-157 and concerns about impurities, product characterization and immune reactions. For injectable GHK-Cu, it identifies limited human safety data and possible aggregation or peptide impurities.
Read the original sourceThree-ingredient GLOW blend evidence
PubMed records
PubMed records for GLOW and its three named ingredients.
The cited PubMed records include studies of individual ingredients and marketing formulas, but no controlled human trial of an identified three-ingredient GLOW formula.
- Ingredient studies and marketing formulas do not establish outcomes for the three-ingredient GLOW blend.
Why is glow in A tier?
The grade reflects the absence of a controlled trial for an identified GLOW formula. GHK-Cu has a positive human wound trial, while BPC-157 and thymosin findings come from separate products and preclinical models. Those component results do not establish the blend's efficacy.